Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SLNO | Warrants (right to buy) | Award | $948 | +2.14K | $0.44 | 2.14K | May 8, 2023 | Common Stock | 2.14K | $1.75 | Direct | F1, F2 | |
transaction | SLNO | Warrants (right to buy) | Award | $1.55K | +3.5K | $0.44 | 3.5K | May 8, 2023 | Common Stock | 3.5K | $2.50 | Direct | F1, F3 |
Id | Content |
---|---|
F1 | The Warrants were acquired pursuant to a Securities Purchase Agreement, dated December 16, 2022, between the Issuer and certain entities and members of the Issuer's management team. The acquisition was approved by the Issuer's Board of Directors and constitutes an exempt acquisition under Rule 16b-3(d)(1) of the Securities Exchange Act of 1934, as amended. |
F2 | The Warrants will expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026. |
F3 | The Warrants will expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026. |